Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26176475 | 0.95 | CXCR4 (0.42) | CXCR4PPARDMEN1KMT2ATSHR | |
| SCHEMBL7452501 | 0.90 | PPARD (0.42) | CXCR4PPARDMEN1KMT2ATSHR | |
| SCHEMBL16317682 | 0.88 | PPARD (0.41) | CXCR4PPARDMEN1KMT2ATSHR | |
| Carbon Monoxide SCHEMBL5005999 | 0.85 | PPARD (0.39) | CXCR4PPARDMEN1KMT2ATSHR | |
| SCHEMBL9003135 | 0.84 | PPARD (0.44) | PPARDTSHRSMN1; SMN2 | |
| SCHEMBL18985137 | 0.83 | CXCR4 (0.43) | CXCR4MEN1KMT2AHRH2HRH1 | |
| SCHEMBL13992769 | 0.81 | CXCR4 (0.51) | CXCR4PPARDMEN1KMT2ATSHR | |
| SCHEMBL7505873 | 0.79 | TSHR (0.41) | PPARDMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL1418450 | 0.79 | TSHR (0.41) | PPARDMEN1KMT2ATSHRSIGMAR1 | |
| SCHEMBL18985125 | 0.79 | CXCR4 (0.40) | CXCR4MEN1KMT2AHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2017101851-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | CXCR4 4674/4885PPARD 397/4885MEN1 2555/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | CXCR4 4674/4885PPARD 397/4885MEN1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.